多批次集采药物首次实现全国范围内统一续标

Core Viewpoint - The continuation of centralized drug procurement in China aims to stabilize clinical medication supply and market expectations for pharmaceutical companies, with over 300 drugs involved in the latest round of procurement [1]. Group 1: Centralized Drug Procurement - The recent centralized procurement process is a key step in ensuring stable clinical medication supply, following the expiration of previous procurement agreements [1]. - The new nationwide unified procurement allows companies to submit a single bid to cover the entire national market, enhancing efficiency compared to previous provincial or inter-provincial procurement methods [1]. - The unified approach is expected to facilitate the establishment of a large national market by consolidating supply and pricing [1]. Group 2: Procurement Details - A total of 316 drugs are included in this round of procurement, with a procurement cycle lasting three years, which is anticipated to further secure clinical medication availability [1]. - The procurement strategy considers multiple factors such as reasonable pricing, reliable quality, stable supply, and sustainable industry development, while also addressing patient medication needs [2].